RPL17 and melanoma: The prognostic and predictive value of ctDNA analysis for IO was demonstrated in multicancer prospective phase II studies where distinct cohorts of patients including high-grade serous ovarian cancer (HGSOC), malignant melanoma, and mixed solid tumours were treated with an anti-PD1 antibody [58,59,60].